| Ident. | Authors (with country if any) | Title |
|---|
| 000601 |
Philip Seeman [Canada] | Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. |
| 000981 |
Craig J. Hudson [Canada] ; Philip Seeman [Canada] ; Mary V. Seeman [Canada] | Parkinson's Disease: Low-Dose Haloperidol Increases Dopamine Receptor Sensitivity and Clinical Response |
| 000B24 |
Philip Seeman [Canada] | Clozapine, a fast-off-D2 antipsychotic. |
| 000C50 |
James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. Brotchie | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. |
| 001038 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 001062 |
Philip Seeman [Canada] ; Michele Tinazzi [Italie] | Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia |
| 001459 |
Terence K. Y. Lai [Canada] ; Philip Seeman [Canada] ; Fang Liu [Canada] | Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia |
| 001889 |
Sheng Chen [Canada] ; Philip Seeman [Canada] ; Fang Liu [Canada] | Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia |
| 002002 |
Philip Seeman [Canada] ; Hong-Chang Guan [Canada] | Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors |
| 002003 |
Philip Seeman [Canada] ; Hong-Chang Guan [Canada] | Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2High receptor |
| 002019 |
Philip Seeman [Canada] | Dopamine D2High receptors measured ex vivo are elevated in amphetamine‐sensitized animals |
| 002305 |
Philip Seeman [Canada] ; Carla Caruso [Argentine] ; Mercedes Lasaga [Argentine] | Memantine agonist action at dopamine D2High receptors |
| 002333 |
Philip Seeman [Canada] | Dopamine D2High receptors moderately elevated by bifeprunox and aripiprazole |
| 002576 |
Philip Seeman [Canada] ; Patrick N. Mccormick [Canada] ; Shitij Kapur [Canada] | Increased dopamine D2High receptors in amphetamine‐sensitized rats, measured by the agonist [3H](+)PHNO |
| 002612 |
Philip Seeman [Canada] | Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2High receptors |
| 002804 |
Philip Seeman [Canada] ; Johannes Schwarz [Allemagne] ; Jiang-Fan Chen [États-Unis] ; Henry Szechtman [Canada] ; Melissa Perreault [Canada] ; G. Stanley Mcknight [États-Unis] ; John C. Roder [Canada] ; Rémi Quirion [Canada] ; Patricia Boksa [Canada] ; Lalit K. Srivastava [Canada] ; Kazuhiko Yanai [Japon] ; David Weinshenker [États-Unis] ; Tomiki Sumiyoshi [Japon] | Psychosis pathways converge via D2High dopamine receptors |
| 002999 |
Philip Seeman [Canada] ; Françoise Ko ; Matth Us Willeit ; Patrick Mccormick ; Nathalie Ginovart | Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors. |
| 002F82 |
Philip Seeman [Canada] | Atypical antipsychotics: mechanism of action. |
| 003071 |
Philip Seeman [Canada] ; Bertha Madras [États-Unis] | Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis |
| 003C09 |
Philip Seeman [Canada] ; D. Roy Corbett [États-Unis] ; Hubert H. M. Van Tol [Canada] | Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors |
| 004392 |
Philip Seeman [Canada] ; Hong-Chang Guan [Canada] ; Hubert H. M. Van Tol [Canada] ; Hyman B. Niznik [Canada] | Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata |
| 004415 |
Philip Seeman [Canada] ; Carla Ulpian [Canada] ; Robert D. Larsen [États-Unis] ; Paul S. Anderson [États-Unis] | Dopamine receptors labelled by PHNO |
| 004D21 |
Philip Seeman [Canada] ; Dimitri Grigoriadis [Canada] | Dopamine receptors in brain and periphery |
| 004D52 |
Philip Seeman [Canada] ; Natalie H. Bzowej [Canada] ; H. Guan [République populaire de Chine] ; Catherine Bergeron [Canada] ; Lawrence E. Becker [Canada] ; Gavin P. Reynolds ; E. D. Bird [États-Unis] ; Peter Riederer [Autriche] ; Kurt Jellinger [Autriche] ; Shuzo Watanabe ; Wallace W. Tourtellotte [États-Unis] | Human brain dopamine receptors in children and aging adults |
| 004D62 |
Philip Seeman [Canada] | Dopamine receptors and the dopamine hypothesis of schizophrenia |
| 004D63 |
Philip Seeman [Canada] ; Mark Guttman [Canada] | Dopamine receptor elevation in denervated tissues |
| 005124 |
Philip Seeman [Canada] | Nomenclature of central and peripheral dopaminergic sites and receptors |
| 005186 |
Tyrone Lee [Canada] ; Philip Seeman [Canada] ; Oleh Hornykiewicz [Canada] ; Juan Bilbao [Canada] ; John Deck [Canada] ; Wallace W. Tourtellotte [États-Unis] | Parkinson's disease: low density and presynaptic location of D3 dopamine receptors |
| 005281 |
Milt Titeler [Canada] ; Joseph L. Tedesco [Canada] ; Philip Seeman [Canada] | Selective labeling of pre-synaptic receptors by 3H-dopamine, 3H-apomorphine and 3H-clonidine; Labeling of post-synaptic sites by 3H-neuroleptics |
